Alaunos Therapeutics (TCRT) Accumulated Expenses (2016 - 2025)
Historic Accumulated Expenses for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to $78000.0.
- Alaunos Therapeutics' Accumulated Expenses fell 7880.43% to $78000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $78000.0, marking a year-over-year decrease of 7880.43%. This contributed to the annual value of $176000.0 for FY2024, which is 8686.57% down from last year.
- Per Alaunos Therapeutics' latest filing, its Accumulated Expenses stood at $78000.0 for Q3 2025, which was down 7880.43% from $265000.0 recorded in Q2 2025.
- In the past 5 years, Alaunos Therapeutics' Accumulated Expenses ranged from a high of $14.0 million in Q1 2021 and a low of $78000.0 during Q3 2025
- Its 5-year average for Accumulated Expenses is $4.5 million, with a median of $3.2 million in 2023.
- As far as peak fluctuations go, Alaunos Therapeutics' Accumulated Expenses plummeted by 874.63% in 2021, and later tumbled by 8801.69% in 2024.
- Over the past 5 years, Alaunos Therapeutics' Accumulated Expenses (Quarter) stood at $6.1 million in 2021, then fell by 10.24% to $5.5 million in 2022, then tumbled by 75.43% to $1.3 million in 2023, then plummeted by 86.87% to $176000.0 in 2024, then plummeted by 55.68% to $78000.0 in 2025.
- Its Accumulated Expenses was $78000.0 in Q3 2025, compared to $265000.0 in Q2 2025 and $231000.0 in Q1 2025.